# Ipilimumab

## Yervoy inj 50mg/10mL

##### 臨採

| TAH Drug Code      | [IYER](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IYER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Unresectable or Metastatic Melanoma: In combination with nivolumab, indicated for patients aged 12 and above with unresectable or metastatic melanoma. 2. Advanced Renal Cell Carcinoma: In combination with nivolumab, indicated as first-line treatment for adult patients with intermediate/poor risk advanced renal cell carcinoma (RCC). 3. Metastatic Colorectal Cancer with High Microsatellite Instability (MSI-H) or Mismatch Repair Deficiency (dMMR): In combination with nivolumab, indicated for adult patients with MSI-H or dMMR metastatic colorectal cancer (CRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on objective response rate, with a requirement for confirmatory trials to verify clinical benefit. 4. Hepatocellular Carcinoma: In combination with nivolumab, indicated for adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on objective response rate and duration of response. Confirmation of clinical benefit is pending in confirmatory trials. 5. Metastatic or Recurrent Non-Small Cell Lung Cancer: (1) In combination with nivolumab, indicated as first-line treatment for adults with metastatic or recurrent non-small cell lung cancer (NSCLC) with PD-L1 expression (?1%) and without EGFR or ALK genomic tumor aberrations. (2) In combination with nivolumab and 2 cycles of platinum-based chemotherapy, indicated as first-line treatment for adults with metastatic or recurrent NSCLC without EGFR or ALK genomic tumor aberrations. 6. Malignant Pleural Mesothelioma: In combination with nivolumab, indicated as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. 7. Esophageal Cancer: In combination with nivolumab, indicated as first-line treatment for adult patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | - Melanoma, Unresectable or metastatic disease: 3 mg/kg IV infusion over 30 minutes with nivolumab 1 mg/kg IV over 30 minutes on the same day every 3 weeks for a MAX of 4 doses or until unacceptable toxicity; after 4 doses give nivolumab as a single agent until disease progression or unacceptable toxicity. - Renal cell carcinoma, Advanced, intermediate or poor risk, first-line: 1 mg/kg with nivolumab 3 mg/kg (30 minute IV infusion on the same day) every 3 weeks for up 4 doses; after completing 4 doses of the combination, administer nivolumab as a single agent until disease progression or unacceptable toxicity. - Metastatic colorectal cancer, MSI-H or dMMR, after progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan: 1 mg/kg IV infusion over 30 minutes immediately following nivolumab 3 mg/kg IV over 30 minutes on the same day, every 3 weeks for up to 4 doses or until intolerable toxicity or disease progression; after completing 4 doses of the combination, administer nivolumab as a single agent. - Liver carcinoma, In patients previously treated with sorafenib: 3 mg/kg IV over 30 minutes, immediately following nivolumab 1 mg/kg IV over 30 minutes administered on the same day, every 3 weeks for up to 4 doses or until intolerable toxicity or disease progression; after completing 4 doses of the combination, administer nivolumab as a single agent. - Non-small cell lung cancer, Metastatic, PD-L1 expression with no EGFR or ALK tumor aberrations, first-line treatment: 1 mg/kg IV over 30 minutes every 6 weeks given with nivolumab 360 mg IV over 30 minutes every 3 weeks until disease progression or unacceptable toxicity, or up to 2 years in patients without disease progression. - Non-small cell lung cancer, Metastatic or recurrent, no EGFR or ALK tumor aberrations, first-line treatment: 1 mg/kg IV over 30 minutes every 6 weeks given with nivolumab 360 mg IV over 30 minutes every 3 weeks and histology-based platinum-doublet chemotherapy every 3 weeks for 2 cycles. Infuse nivolumab followed by ipilimumab and then chemotherapy on the same day. Continue ipilimumab plus nivolumab for up to 2 years, until disease progression, or unacceptable toxicity. - Malignant mesothelioma of pleura: 1 mg/kg IV infusion over 30 minutes every 6 weeks with nivolumab 360 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. - Advanced or metastatic esophageal squamous cell carcinoma (ESCC): 1 mg/kg IV infusion over 30 minutes every 6 weeks with nivolumab 360 mg IV infusion over 30 minutes every 3 weeks OR with nivolumab 3mg/kg every 2 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Unknown. Hypersensitivity to ipilimumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common: Pruritus (17-53%), Weight decreasing (10-32%), Abdominal pain (10-30%), Colitis (4-31%), Constipation (14-21%), Decrease in appetite (14-35%), Diarrhea (22-54%), Nausea (20-44%), Vomiting (12-31%), Arthralgia (10-23%), Musculoskeletal pain (14-41%), Asthenia (<1%), Dizziness (11-20%), Headache (11-33%), Insomnia (10-18%), Cough (13-37%), Dyspnea (13-27%), Pneumonia (10-14%), Fatigue (27-62%), Fever (14-40%). Serious: Heart failure, Hypersensitivity angiitis (<1%), Myocarditis (<1%), Pericarditis (<1%), Temporal arteritis (<1%), Vascular disorder (<1%), Vasculitis (<1%), Dermatitis, Erythema multiforme (<1%), Erythroderma, Psoriasis (<1%), Rash (15-53%), Stevens-Johnson syndrome, Toxic epidermal necrolysis, Adrenal Cushing's syndrome, Adrenal insufficiency (7-18%), Diabetes mellitus (2.7%), Disorder of endocrine system (28%), Hyperglycemia (6-8%), Hyperthyroidism (10-12%), Hypogonadism, Hypophysitis (4-13%), Hypopituitarism, Hypothyroidism (14-20%), Thyroiditis (2.7%), Duodenitis (<1%), Gastritis (<1%), Pancreatitis (1.3%), Perforation of intestine (<10%), Aplastic anemia (<1%), Autoimmune hemolytic anemia, Cytopenia (2.5%), Eosinophil count above reference range (2.1%), Histiocytic necrotizing lymphadenitis (<1%), Hepatitis (4.1-21%), Drug reaction with eosinophilia and systemic symptoms, Graft versus host disease, Sarcoidosis (<1%), Systemic inflammatory response syndrome (<1%), Transplanted organ rejection (<1%), Arthritis (<1%), Eaton-Lambert syndrome (<1%), Myasthenia gravis (<1%), Myositis (<1%), Polymyalgia rheumatica (<1%), Polymyositis (<1%), Rhabdomyolysis (<1%), Demyelination of spinal cord (<1%), Encephalitis (<1%), Guillain-Barre syndrome (<1%), Meningitis (<1%), Motor dysfunction (<1%), Myelitis (<1%), Neuropathy (2%), Blepharitis (<1%), Blurred vision, Episcleritis (<1%), Iritis (<1%), Myasthenia gravis, ocular, Orbital myositis (<1%), Scleritis (<1%), Uveitis (<1%), Vogt-Koyanagi-Harada disease, Hearing loss, Neurosensory (<1%), Nephritis (4.1%), Renal failure (<1%), Pneumonitis (3.9-10%), Infusion reaction (Up to 12%).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/ipilimumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

